Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma (Q33349428)

26 July 2017

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma (English)

1 reference

26 July 2017

recurrent osteosarcoma

1 reference

Paul A Meyers

5

0 references

Richard G Gorlick

object named as

Richard Gorlick

4

0 references

Robert G. Maki

object named as

Robert G Maki

6

0 references

Leonard H Wexler

7

object named as

Leonard Wexler

1 reference

26 July 2017

10

Andrew G Huvos

1 reference

26 July 2017

2

E Anders Kolb

1 reference

26 July 2017

11

Allen M Goorin

1 reference

26 July 2017

1

Caroline Laverdiere

1 reference

26 July 2017

8

George D Demetri

1 reference

26 July 2017

Jeffrey G Supko

3

1 reference

26 July 2017

John H Healey

9

1 reference

26 July 2017

Rochelle Bagatell

12

1 reference

26 July 2017

Ana Ruiz-Casado

13

1 reference

26 July 2017

Cecilia Guzman

14

1 reference

26 July 2017

Jose Jimeno

15

1 reference

26 July 2017

David Harmon

16

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

26 July 2017

1 reference

26 July 2017

98

1 reference

26 July 2017

832-840

1 reference

26 July 2017

4

1 reference

The contribution of salvage surgery to the management of childhood osteosarcoma

26 July 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Increased DNA Binding Specificity for Antitumor Ecteinascidin 743 through Protein−DNA Interactions?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Unique features of the mode of action of ET-743.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

One of the most interesting pro-apoptotic proteins recently identified is the TNF-related apoptosis-inducing ligand (TRAIL)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Cytotoxic agents in the era of molecular targets and genomics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11563

7 January 2021

Identifiers

DOI

10.1002/CNCR.11563

1 reference

26 July 2017

1 reference